BioLineRx launches Phase Ib/II combination trial for acute myeloid leukaemia

Israeli biopharmaceutical firm BioLineRx has launched a Phase Ib/II clinical trial (BATTLE) of BL-8040 in combination with Genentech ’s anti-PDL1 immunotherapy atezolizumab (Tecentriq) in patients suffering from acute myeloid leukaemia (AML).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news